RxDoctor Payments DataLook up a doctor →

Anna Boron, MD

Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1548445182

Payments from drug & device makers

$32,445in general payments, 2019–2025

Across 863 payments — averaging $37.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$9K
  • Corcept Therapeutics$6K
  • Novo Nordisk$3K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Boehringer Ingelheim$985
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott27$9,234
Corcept Therapeutics57$5,636
Novo Nordisk86$3,053
Lilly USA, LLC90$1,484
Amgen(2 entities)47$1,147
Boehringer Ingelheim40$985
AbbVie40$917
Recordati_rare_diseases_inc.13$873
Dexcom, Inc.31$766
AstraZeneca(2 entities)32$696
Radius Health, Inc.25$584
Medtronic(2 entities)29$581
Insulet Corporation40$546
Merck45$542
Mannkind Corporation23$530
Sanofi-aventis U.S. LLC31$516
Xeris Pharmaceuticals, Inc.26$488
Tandem Diabetes Care, Inc.13$296
Bayer14$240
Ascensia Diabetes Care US Inc.7$239
Zealand Pharma US, Inc.13$221
Amneal Pharmaceuticals LLC12$210
Cequr Corporation3$187
Antares Pharma, Inc.9$178
Aimmune Therapeutics, Inc.6$162
Tolmar, Inc.9$150
Intuity Medical Inc7$141
IBSA Pharma Inc.7$131
Amryt Pharma Holdings Ltd5$126
Currax Pharmaceuticals LLC7$105
Sequel Med Tech, LLC2$94
Ascendis Pharma Endocrinology Inc4$92
Esperion Therapeutics, Inc.4$81
Pfizer4$80
Ipsen Biopharmaceuticals, Inc4$80
EUSA Pharma (US) LLC3$73
Verity Pharmaceuticals Inc.3$70
Alnylam Pharmaceuticals Inc.3$65
Astellas Pharma US Inc2$65
BETA Bionics, Inc.3$65
Nestle Healthcare Nutrition Inc.3$59
Amphastar Pharmaceuticals, Inc.3$55
Vivus LLC4$49
Halozyme Inc2$48
Averitas Pharma Inc.2$45
Ultragenyx Pharmaceutical Inc.2$43
Takeda Pharmaceuticals U.S.A., Inc.2$38
Clarus Therapeutics Inc.2$35
Embecta Corp.1$35
Nevro Corp.2$35
Madrigal Pharmaceuticals1$31
Acella Pharmaceuticals, LLC2$31
Neurocrine Biosciences, Inc.1$30
Kyowa Kirin, Inc.1$29
Novartis1$25
GRT US Holding, Inc.1$23
Alvogen Inc1$22
Acerus Pharmaceuticals Corporation1$17
Valeritas, Inc.1$16
Johnson & Johnson1$15

How this compares

$32,445 in reported general payments places this provider in the 85th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona →

Medicare billing

Part B allowed, 2024
$113,893
Medicare patients
430
Services billed
1,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Phoenix

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →